RT Journal Article
SR Electronic
T1 The causal effects of body mass index (BMI) on childhood symptoms of depression, anxiety disorder, and attention-deficit hyperactivity disorder: a within family Mendelian randomization study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.17.21263612
DO 10.1101/2021.09.17.21263612
A1 Hughes, Amanda M
A1 Morris, Tim
A1 Ayorech, Ziada
A1 Tesli, Martin
A1 Ask, Helga
A1 Reichborn-Kjennerud, Ted
A1 Andreassen, Ole A.
A1 Magnus, Per
A1 Helgeland, Øyvind
A1 Johansson, Stefan
A1 Njølstad, Pål
A1 Smith, George Davey
A1 Havdahl, Alexandra
A1 Howe, Laura D
A1 Davies, Neil M
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.17.21263612.abstract
AB Objectives Higher BMI in childhood predicts neurodevelopmental and emotional problems, but it is unclear if these associations are causal. Previous genetic studies imply causal effects of childhood BMI on depression and attention-deficit hyperactivity disorder (ADHD), but these observations might also reflect effects of demography and the family environment. We used within-family Mendelian randomization, which accounts for familial effects by controlling for parental genotype, to investigate the impact of BMI on symptoms of depression, anxiety, and ADHD symptoms at age 8.Methods This study is based on the Norwegian Mother, Father and Child Cohort Study (MoBa) and uses data from the Medical Birth Registry of Norway (MBRN). Participants were 26,370 8-year-old children (48.7% female) born 1999-2009, together with their parents. We applied multivariable regression, classic Mendelian randomization (‘classic MR’), and within-family Mendelian randomization (‘within-family MR’). We report estimates of the effects of the child’s own BMI, mother’s BMI, and father’s BMI on the child’s depressive, anxiety, and ADHD symptoms, reported by mothers when the child was aged 8.Results In multivariable regression, higher BMI was marginally associated with more depressive and ADHD symptoms, and associated with fewer anxiety symptoms, in 8-year-old children. Classic MR models implied a causal effect of children’s higher BMI on higher depressive and ADHD symptoms, and to a lesser degree, lower anxiety symptoms. In within-family MR models, there was less evidence that children’s own BMI affected any of these symptoms. For example, a 5kg/m2 increase in BMI was associated with 0.04 standard deviations (SD) higher depressive symptoms (95% CI -0.01 to 0.09) in multivariable regression, with corresponding effect estimates of 0.41 SD (95% CI 0.10 to 0.56) in classic MR and 0.08 SD (95% CI -0.25 to 0.42) in within-family MR. Within-family MR suggested that maternal but not paternal BMI was associated with children’s depressive symptoms.Conclusions The influence of childhood BMI on depressive, anxiety and ADHD symptoms may have been overstated by MR approaches that do not account for parental genotype. Factors correlated with maternal BMI may influence offspring symptoms of depression.What is already known on this topicChildren with high body mass index have been found to have more symptoms of depression, anxiety, and attention-deficit hyperactivity disorder.It is not known whether higher body weight increases risk of these symptoms, these symptoms increase body weight, or environmental or genetic factors cause both independently.Previous genetic studies have used samples of unrelated individuals to assess the causal impact of BMI on these symptoms, but these studies may have been biased by demographic and familial effects, for example the impact of risk factors correlated with parent’s BMI.What this study addsWhen demographic and family-level effects were controlled for, we found less evidence of an effect of a child’s own BMI on depressive, anxiety, or ADHD symptoms, compared with classic MR approaches that do not account for parental genotype.We found evidence that demographic or familial factors correlated with parental BMI may independently impact children’s outcomes.Competing Interest StatementOAA has received speaker's honorarium from Sunovion and Lundbeck and is a consultant for HealthLytix.Funding StatementThis research was funded by the Health Foundation (award number 807293) as part of the Social and Economic Value of Health Programme. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (#229624). Individual co-authors area also supported by specific sources of funding. ZA is supported by a Marie Skłodowska-Curie Fellowship from the European Union (894675). TR is supported by the Research Council of Norway (274611 PI: Reichborn-Kjennerud). OAA is funded by the Research Council of Norway (223273) and EU H2020 RIA (847776 CoMorMent). OH is supported by the University of Bergen, Norway. SJ was supported by Helse Vest's Open Research Grant (grants #912250 and F-12144), the Novo Nordisk Foundation (grant NNF19OC0057445) and the Research Council of Norway (grant #315599). LDH is supported by a Career Development Award from the UK Medical Research Council (MR/M020894/1); The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit [MC_UU_12013/1] (AH, LDH, NMD, GDS, TM].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency and The Regional Committees (REC) for Medical and Health Research Ethics. The REC South East Norway, one of four in Norway, was the ethical committee that evaluated the ethics of this study. Approval from the REC was granted (2016/1702). Informed consent was obtained from each MoBa participant upon recruitment, which included consent to link to the Medical Birth Registry of Norway (MBRN). The MoBa cohort is now based on regulations related to the Norwegian Health Registry Act.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to data sets for replication should submit an application to datatilgang{at}fhi.no. Access to data sets requires approval from The Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa.